<DOC>
	<DOC>NCT01357109</DOC>
	<brief_summary>The purpose of the study is to investigate if oral treatment with bosentan improves endothelium-dependent vasodilatation in patients with type 2 diabetes and microangiopathy.</brief_summary>
	<brief_title>Effect of Bosentan on Endothelial Function in Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Bosentan</mesh_term>
	<criteria>1. Diabetes mellitus type 2 of &gt;2 years duration 2. Albuminuria 1. Age &gt;80 years 2. Myocardial infarction/unstable angina within three months prior to randomisation 3. Decompensated congestive heart failure or functional class 3 and 4. 4. Changes in dosage of any vasodilator drugs during the preceding six weeks 5. Women of fertile age. 6. Impaired hepatic function (2 times upper normal limit of aminotransferases ASAT and ALAT) 7. Ongoing treatment with glibenclamide, cyclosporin or warfarin 8. Any concomitant disease or condition that may interfere with the possibility for the patient to comply with or complete the study protocol 9. Participant in an ongoing study 10. Unwillingness to participate following oral and written information</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2007</verification_date>
</DOC>